Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04855097 · ClinicalTrials.gov registry record · NA
Evaluation of Blood Volume Analysis- Guided Management of Decompensated Heart Failure
A NA study, sponsored by Daxor Corporation.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT04855097 is a NA study that has completed, run by Daxor Corporation. The registered enrollment target is 32 participants.
The verdict
NCT04855097, a NA study, has completed, sponsored by Daxor Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
Diuretic therapy is first-line treatment for acute decompensated heart failure. However, accurate assessment and management of patient blood volume is challenged by the limitations of physical exam and surrogate markers for blood volume. The study primary objective is to determine if goal-directed care as quantified by direct Blood Volume Analysis (Daxor BVA-100™) in addition to usual care results in more appropriate treatment and consistent achievement of euvolemia.
Interventions
- DIAGNOSTIC_TEST BVA-100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-05-01 |
| Est. Completion | 2022-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04855097
The ClinicalTrials.gov registry entry for NCT04855097 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daxor Corporation, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BVA-100 is the first listed.
NCT04855097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04855097 about?
NCT04855097 is a clinical study titled "Evaluation of Blood Volume Analysis- Guided Management of Decompensated Heart Failure". Diuretic therapy is first-line treatment for acute decompensated heart failure. However, accurate assessment and management of patient blood volume is challenged by the limitations of physical exam and surrogate markers for blood volume. The study primary objective is to determine if goal-directed c...
What is the current status of trial NCT04855097?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2022-05-01. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT04855097?
The interventions under investigation include: BVA-100 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04855097?
This trial is sponsored by Daxor Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.